Nuvation Bio Inc. (NUVB)

NYSE • Healthcare

$4.57

-$0.12 (-2.8%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$4.62

Previous Close$4.57

Day Range$4.44 - $4.66

Avg. Volume (3M)5.7M

Market Cap$1.6B

52 Week Range

$3.92$9.75

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$31.6M100%

Gross Profitminus cost of goods$30.7M97%

Fundamentals & Financials

Revenue (TTM)

$169.9M

Net Income (TTM)

-$149.8M

EPS (TTM)

-$0.43

ROA (TTM)

-20.12%

Current Ratio

8.37

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

0.0%Q3 2025-$0.17

+5.9%Q4 2025-$0.16

0.0%Q1 2026-$0.11

+135.7%Q2 2026$0.01

-5.9%Q3 2026-$0.15

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -5.9%

Nuvation Bio's second fiscal quarter of 2026, reported Aug. 6, topped revenue consensus even as adjusted EPS missed. Revenue rose about 556% to roughly $31.7 million from about $4.8 million a year ago, beating the roughly $27.0 million consensus by about 17%. Adjusted EPS of -$0.15 missed the roughly -$0.14 estimate by about 6%, but improved about 12% from -$0.17 a year ago. Gross margin held near 97%, while operating margin was around -161% and operating income stayed negative at about $51.0 million. Net income was about negative $62.8 million, down about 7% from about negative $59.0 million a year ago. The company also reported negative operating cash flow of about $5.1 million and repurchased about $17.1 million of stock. Consensus for the next period calls for adjusted EPS of -$0.13 on revenue of $38.6 million.

Next report — what to expect

Nuvation Bio Inc. (NUVB) reports next on November 2, 2026. The Street is looking for consensus EPS of -$0.12 on revenue of $35.6 million. For trailing context, revenue rose +555.6% year over year last quarter. NUVB has beaten EPS in 2 of 8 most recent quarters.

View full earnings history

About Nuvation Bio Inc.

Nuvation Bio Inc. is a NYSE-listed biotechnology company that discovers and develops cancer therapies. In FY2025, it recorded $62.9 million in revenue. The company operates as a clinical-stage biopharmaceutical business focused on advancing treatments for oncological conditions through a pipeline of targeted small molecules and a drug-drug conjugate platform.

Name

Nuvation Bio Inc.

CEO

David T. Hung

Website

www.nuvationbio.com

Industry

Healthcare

Year Founded

2018

Employees

305

Today's Snapshot

AI-generated

NUVB closed 2.8% below yesterday's close, in line with a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level. NUVB reports earnings on 4 November.

Trading Volume

Below 10d avg (4.8M)

3.1M

vs S&P 500 Today

Underperforming Market

-2.25%

Updated: October 23, 2026 at 20:27 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

NUVB is trading around 4.57 and presents a decisively negative technical profile consistent with a strong sell. The stock sits below its short-, medium- and long-term moving averages, and ADX above 36 confirms a strong downtrend. Momentum and oscillator readings are weak, volatility is elevated relative to price and the pivot is above the market, while on‑balance volume remains heavily negative, signaling sustained distribution. These factors combine to show persistent selling pressure rather than stabilization. Technical takeaway: Strong Sell.

All signals